title: Dipyridamole thallium-201 scintigraphy for early risk stratification of patients after uncomplicated myocardial infarction.
abstract: OBJECTIVE
  To determine the safety and prognostic value of dipyridamole thallium-201 scintigraphy performed in patients within three to five days of acute myocardial infarction, including those receiving thrombolytic treatment.
  
  
  METHODS
  A prospective study of dipyridamole thallium-201 scintigraphy in patients early after acute myocardial infarction.
  
  
  METHODS
  University hospital.
  
  
  METHODS
  200 patients who were clinically uncomplicated at day 3 after infarction, 92 (46%) of whom had received thrombolysis.
  
  
  METHODS
  Incidence of cardiac death, non-fatal reinfarction, readmission to hospital for unstable angina, or non-elective revascularisation procedure within six months' follow up.
  
  
  RESULTS
  No patient had a serious complication from the dipyridamole study. At six month follow up, 55 patients (28%) had suffered a defined cardiac event. Patients who received thrombolysis had the same extent of thallium-201 redistribution and the same occurrence of subsequent cardiac events as those not receiving thrombolysis. Patients who subsequently had an event had more myocardial segments showing thallium-201 redistribution than event free patients: 2.7 (SD 1.9) v 1.2 (1.4), respectively (p < 0.001). Among all clinical and scintigraphic variables, multivariate analysis identified the extent of thallium-201 redistribution as the only independent predictor of outcome (p < 0.001). Among 63 patients (32%) of the study cohort who showed more than two myocardial segments with thallium-201 redistribution, the adjusted risk ratio for a cardiac event was 7.5 (95% confidence interval 2.9 to 19.1) compared with patients without any redistribution.
  
  
  CONCLUSIONS
  Dipyridamole thallium-201 scintigraphy can be performed safely within a few days of the event in patients with uncomplicated myocardial infarction, including those who received thrombolysis, and can identify a subgroup of patients at high risk of future ischaemic events.
authors.affiliation: Department of Medicine, University of Western Australia, Perth, Australia. jhung@cyllene.uwa.edu.au
authors.forename: J
authors.initials: J
authors.lastname: Hung
authors.forename: M
authors.initials: M
authors.lastname: Moshiri
authors.forename: G N
authors.initials: GN
authors.lastname: Groom
authors.forename: A A
authors.initials: AA
authors.lastname: Van der Schaaf
authors.forename: R W
authors.initials: RW
authors.lastname: Parsons
authors.forename: M E
authors.initials: ME
authors.lastname: Hands
mesh_terms: D000368:Aged; D004176:Dipyridamole; D005260:Female; D005500:Follow-Up Studies; D006321:Heart / Q000000981:diagnostic imaging*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging* / Q000628:therapy; D011379:Prognosis; D011446:Prospective Studies; D015635:Radionuclide Ventriculography; D012008:Recurrence; D012044:Regression Analysis; D013794:Thallium Radioisotopes; D015912:Thrombolytic Therapy; D014665:Vasodilator Agents
chemical_list: D013794:Thallium Radioisotopes; D014665:Vasodilator Agents; D004176:Dipyridamole